{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:09:58Z","timestamp":1785798598428,"version":"3.56.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":462,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>A recent study suggested that women with heart failure and heart failure reduced ejection fraction might hypothetically need lower doses of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (\u2009=\u2009renin-angiotensin-system inhibitors) and \u03b2-blockers than men to achieve the best outcome. We assessed the current medical treatment of heart failure reduced ejection fraction in men and women in a large contemporary cohort and address the hypothetical impact of changing treatment levels in women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This analysis is part of a large contemporary quality of heart failure care project which includes 5320 (64%) men and 3003 (36%) women with heart failure reduced ejection fraction. Detailed information on heart failure therapy prescription and dosage were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Women less often received renin-angiotensin-system inhibitors (79% vs 83%, p\u2009&amp;lt;\u20090.01), but more often \u03b2-blockers (82% vs 79%, p\u2009&amp;lt;\u20090.01) than men. Differences in guideline-recommended target doses between sexes were relatively small. Implementing a hypothetical sex-specific dosing schedule (at 50% of the current recommended dose in the European Society of Cardiology guidelines in women only) would lead to significantly higher levels of women receiving appropriate dosing (\u03b2-blocker 87% vs 54%, p\u2009&amp;lt;\u20090.01; renin-angiotensin-system inhibitor 96% vs 75%, p\u2009&amp;lt;\u20090.01). Most interestingly, the total number of women with &amp;gt;100% of the new hypothetical target dose would be 24% for \u03b2-blockers and 52% for renin-angiotensin-system inhibitors, which can be considered as relatively overdosed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this large contemporary heart failure registry, there were significant but relatively small differences in drug dose between men and women with heart failure reduced ejection fraction. Implementation of the hypothetical sex-specific target dosing schedule would lead to considerably more women adequately treated. In contrast, we identified a group of women who might have been relatively overdosed with increased risk of side-effects and intolerance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1177\/2047487320923185","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T03:00:34Z","timestamp":1589338834000},"page":"957-965","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction"],"prefix":"10.1093","volume":"28","author":[{"given":"Jesse F","family":"Veenis","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Medical Center Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter Brunner-La","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard C M","family":"Linssen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Group Twente, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayten","family":"Erol-Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maasstad Ziekenhuis, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen C B","family":"Pronk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Elisabeth-TweeSteden Ziekenhuis, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domien J M","family":"Engelen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Diakonessenhuis, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob M","family":"van Tooren","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St Antonuis Ziekenhuis, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetty J J","family":"Koornstra-Wortel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maasziekenhuis Pantein, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno W","family":"Hoes","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J","family":"Brugts","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the CHECK-HF investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"2022030617350529600_zwaa359-B1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.cardfail.2009.01.010","article-title":"Are there any significant differences between females and males in the management of heart failure? Gender aspects of an elderly population with symptoms associated with heart failure","volume":"15","author":"Alehagen","year":"2009","journal-title":"J Card Fail"},{"key":"2022030617350529600_zwaa359-B2","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":". Circulation"},{"key":"2022030617350529600_zwaa359-B3","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"2022030617350529600_zwaa359-B4","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2022030617350529600_zwaa359-B5","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31792-1","article-title":"Identifying optimal doses of heart failure medications in men compared with women: A prospective, observational, cohort study","author":"Santema","year":"2019","journal-title":"Lancet"},{"key":"2022030617350529600_zwaa359-B6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12471-018-1103-7","article-title":"Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: Design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry","volume":"26","author":"Brugts","year":"2018","journal-title":"Neth Heart J"},{"key":"2022030617350529600_zwaa359-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: The CHECK-HF Registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022030617350529600_zwaa359-B8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"2022030617350529600_zwaa359-B9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/2047487317744363","article-title":"Age and gender differences in medical adherence after myocardial infarction: Women do not receive optimal treatment \u2013 the Netherlands Claims Database","volume":"25","author":"Eindhoven","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2022030617350529600_zwaa359-B10","doi-asserted-by":"crossref","DOI":"10.1177\/2047487319900875","article-title":"Sex differences in optimal medical therapy following myocardial infarction according to left ventricular ejection fraction","author":"Hay","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2022030617350529600_zwaa359-B11","article-title":"Sex differences in hypertrophic cardiomyopathy: Time to tailor risk stratification and therapy?","author":"Constantine","journal-title":"Eur J Prev Cardiol"},{"key":"2022030617350529600_zwaa359-B12","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1136\/hrt.2006.099523","article-title":"Management of patients with heart failure in clinical practice: Differences between men and women","volume":"94","author":"Lenzen","year":"2008","journal-title":"Heart"},{"key":"2022030617350529600_zwaa359-B13","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/clc.20476","article-title":"Influence of gender on long-term prognosis of patients with chronic heart failure seen in heart failure clinics","volume":"33","author":"Jimenez-Navarro","year":"2010","journal-title":"Clin Cardiol"},{"key":"2022030617350529600_zwaa359-B14","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ahj.2009.07.012","article-title":"Baseline differences in the HF-ACTION trial by sex","volume":"158","author":"Pina","year":"2009","journal-title":"Am Heart J"},{"key":"2022030617350529600_zwaa359-B15","doi-asserted-by":"crossref","DOI":"10.1089\/jwh.2017.6461","article-title":"Gender differences in utilization of specialized heart failure clinics","author":"Abrahamyan","year":"2018","journal-title":"J Womens Health (Larchmt)"},{"key":"2022030617350529600_zwaa359-B16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hfc.2018.08.003","article-title":"Heart failure with reduced ejection fraction in women: Epidemiology, outcomes, and treatment","volume":"15","author":"Mentzer","year":"2019","journal-title":"Heart Fail Clin"},{"key":"2022030617350529600_zwaa359-B17","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2003.05.012","article-title":"Gender differences in advanced heart failure: Insights from the BEST study","volume":"42","author":"Ghali","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022030617350529600_zwaa359-B18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2022030617350529600_zwaa359-B19","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: Results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"2022030617350529600_zwaa359-B20","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2022030617350529600_zwaa359-B21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/01.CIR.103.3.375","article-title":"Sex differences in the prognosis of congestive heart failure: Results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II)","volume":"103","author":"Simon","year":"2001","journal-title":"Circulation"},{"key":"2022030617350529600_zwaa359-B22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/01.CIR.0000012546.20194.33","article-title":"Metoprolol CR\/XL in female patients with heart failure: Analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF)","volume":"105","author":"Ghali","year":"2002","journal-title":"Circulation"},{"key":"2022030617350529600_zwaa359-B23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2022030617350529600_zwaa359-B24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2022030617350529600_zwaa359-B25","article-title":"Metoprolol dose equivalence in adult men and women based on gender differences: Pharmacokinetic modeling and simulations","author":"Eugene","journal-title":"Med Sci (Basel)"},{"key":"2022030617350529600_zwaa359-B26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurheartj\/ehv598","article-title":"Gender in cardiovascular diseases: Impact on clinical manifestations, management, and outcomes","volume":"37","author":"Regitz-Zagrosek","year":"2016","journal-title":"Eur Heart J"},{"key":"2022030617350529600_zwaa359-B27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2022030617350529600_zwaa359-B28","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): A randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"2022030617350529600_zwaa359-B29","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa021266","article-title":"Sex-based differences in the effect of digoxin for the treatment of heart failure","volume":"347","author":"Rathore","year":"2002","journal-title":"N Engl J Med"},{"key":"2022030617350529600_zwaa359-B30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"},{"key":"2022030617350529600_zwaa359-B31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijcard.2014.07.108","article-title":"The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease","volume":"176","author":"Brugts","year":"2014","journal-title":"Int J Cardiol"},{"key":"2022030617350529600_zwaa359-B32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0895-4356(94)00231-E","article-title":"Angiotensin converting enzyme inhibitor associated cough: A population-based case-control study","volume":"48","author":"Visser","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"2022030617350529600_zwaa359-B33","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/eurheartj\/ehv161","article-title":"Gender differences in the effect of cardiovascular drugs: A position document of the Working Group on Pharmacology and Drug Therapy of the ESC","volume":"36","author":"Rosano","year":"2015","journal-title":"Eur Heart J"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2047487320923185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2047487320923185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/9\/957\/42747934\/zwaa359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/28\/9\/957\/42747934\/zwaa359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T17:35:32Z","timestamp":1646588132000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/28\/9\/957\/6353484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5,12]]},"published-print":{"date-parts":[[2021,8,9]]}},"URL":"https:\/\/doi.org\/10.1177\/2047487320923185","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2020,5,12]]}}}